Fast-growing firm to further innovate its brand-to-local digital marketing platform to fuel continued growth.
Veran Medical Technologies Inc., a privately-held medical device company and leader in image-guided endobronchial and percutaneous technology for diagnosis of lung cancer and therapy delivery, has completed a $30.6 million financing, led by Versant Ventures and River Cities Capital Funds.
On June 5, EndoChoice Holdings Inc. (NYSE:GI), completed an IPO, raising nearly $106 million on the New York Stock Exchange. River Cities Fund IV first invested in EndoChoice in 2008 and is the second-largest stakeholder in the company.
TissueTech, Inc. receives $15 million in growth equity financing from River Cities and Ballast Point.
Lattice Engines, the leading provider of predictive marketing and sales applications, today announced it has closed a $28 million Series D financing round. River Cities Capital Funds and Piper Jaffray Merchant Banking led the round.